Issue Areas

Drug Pricing

Prescription drug prices continue to rise, threatening to make vital therapies unaffordable for many patients.
Learn more

Kaiser Permanente believes it is time for a new legal and policy landscape for drug pricing that rewards innovation and discovery, but also provides medicines at prices patients and the health care system can afford.

Featured content Events Our experts

Featured content

Restoring Provider Confidence In FDA-Approved Drugs
Evolving nature of evidence required by FDA to approve new drugs
Drug policy 101: Kaiser Permanente’s Approach to Pharmaceutical Detailing
pile of 20 dollar bills and medicine containers on white background
How pharmaceutical marketing affects decisions about patient care
Priti Krishtel
Building a bigger table for a more equitable drug development system
Biosimilars at Kaiser Permanente
The Medicaid Drug Rebate Program and the impact of “best price” rules
pharma marketing 101
Drug policy 101: Pharmaceutical marketing tactics
When the best prescription is deprescribing
Polly Webster
The promise — and challenges — of gene therapy
Rena Conti
Determining drug value: Let’s start with the evidence
Drug policy 101: Breaking down different types of drug products
Drug policy 101: The state of the pharmaceutical evidence base
Samantha-Dupont
How to save the patent system in 3 easy steps
Anthony Barrueta
It’s time to change drug companies’ harmful marketing practices
Sameer Ansare
The price Is wrong: Why we need to curb prices on biologics to protect patients
Drug policy 101: Biosimilars
Lori Potter
A deeper dive: Recommendations for strengthening the FDA’s REMS program to protect patients
Murray-Ross
Our thoughts on HHS’s blueprint to lower drug prices: It’s time for a new legal and policy landscape
Norman Ornstein
Reflections on high drug pricing in America: Where we are and where we’re headed
Institute for Health Policy Staff
A provider and payor’s perspective on drug pricing
Institute for Health Policy Staff
What the US can learn about drug pricing from Australia, the U.K. and Germany
Murray-Ross
Sovaldi, Harvoni, and why it’s different this time

Drug Policy 101 Series

Drug policy 101: Kaiser Permanente’s Approach to Pharmaceutical Detailing
pile of 20 dollar bills and medicine containers on white background
How pharmaceutical marketing affects decisions about patient care
pharma marketing 101
Drug policy 101: Pharmaceutical marketing tactics
Drug policy 101: Breaking down different types of drug products
Drug policy 101: The state of the pharmaceutical evidence base
Drug policy 101: Drug patents
Drug policy 101: Biosimilars
Drug policy 101: FDA risk evaluation and mitigation strategy (REMS)
Drug Policy 101: Pay-for-delay

Drug pricing experts

Click a speaker to view their full bio.

Barbara DiPietro
Barbara DiPietro, MD
Senior Director of Policy, National Health Care for the Homeless Council
Margot Bushel
Margot Kushel, MD
Director of the UCSF Benioff Homelessness and Housing Initiative
Rishi Miranda
Rishi Manchanda, MD
President & CEO, HealthBegins
Cecilia Echeverría
Cecilia Oregón, MPP, MPH
Executive Director, Kaiser Permanente Institute for Health Policy
Jacqueline Waggoner
Jacqueline Waggoner
President, Solutions Division, Enterprise Community Partners, Inc.